A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...
No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ... She’ll now continue to share her experiences through EMD Serono’s ongoing “I’m Ready” campaign.
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...
Dr Reddy's, Merck Serono in pact to develop biotech drugs Germany's Merck KGaA, have entered into a partnership to co-develop a portfolio of biosimilar compounds (biotechnology drugs) in the ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback